Member Info for Brighty1

The SNG share price has had a track record in the last 2 years of dropping just ahead of BIG news. I'm here for £10 a share (at least). Good luck all SNG investors, Brighty

I agree. TEK has huge potential to multi-bag from here. This could be 10 or 15 times higher, at least in the next year or so. News in bound soon on many fronts. It is clear that TEK's strategy of creating value from breakthrough Uni tech is starting to really pay off with Guident, Salarius, Lucyd and Belluscura. Good luck, Brighty

The RNS from 11th October said it all for me: "Dunrobin is evaluated by Baron to be one of the few remaining targets yet to be drilled in the UK North Sea with estimated gross mean prospective resources of the order of 100 MMbbl (a non-SPE PRMS compliant estimate). The Beatrice field c.20km north of Dunrobin produced over 140 MMbbl from the same petroleum system. Well costs are expected to be modest at c. £7 million gross as the prospect lies in shallow water of less than 100 metres and the total drilling depth of the well is prognosed to be approximately 660 metres".

Whilst it has clearly taken a very long time to reach this stage Dunrobin is starting to look very very interesting for a mega multibag soon for BOIL shareholders.

Good luck, Brighty

How much would a major pharma have to pay for SNG soon? Amgen paid $13 billion in cash for Otezla. So, right now probably £10+ a share at least. The longer this is drawn out the bigger the price SNG will be able to command imo. If you research the licencing and takeover transactions that have occurred in the pharmaceutical sector recently you will see that many are significant billion pound deals. Good luck, Brighty

Exactly and we know already from the data that SNG001 boosts lung defences. This equates to SNG being the perfect treatment for influenza AND Covid. Richard Marsden and Sir Stephen Holgate have been talking up "a real breakthrough for UK science", so watch this space. It's looking very good here for the next chapter of the SNG story - and for UK science in particular. Good luck all SNG investors, Brighty

This should see TXP hit £2 a share soon. Normal service resumed. Happy Monday indeed. Good luck, Brighty

Exactly Stas, how ABDX is more than half its 96p IPO price is quite outrageous - all thanks to the Govt not paying its bills on time. The good news is that the company has its AbC-19™ test. which has showed sensitivity of 97.58% and specificity of 99.59% as defined by the MHRA. Plus don't forget the quote from the RNS a few months ago:“In addition, IgG antibodies to the SARS-CoV-2 virus were detected 10 months after infection. Understanding the longevity of COVID-19 antibodies is important both immunologically and in helping to guide pandemic exit protocols”. All very impressive and when antibody testing kicks in ABDX will be at the forefront of this.

It is fair to say that when the tide turns with the share price it is going to rocket. The frustrating element is all this" Build Back Better" and "Levelling Up" rhetoric from the Govt is just hot air. Message to UK Govt: "Actions speak louder than words". The UK Gov’t needs to stop messing about with inferior tests and utilise the Abingdon science. It clearly works. It really is time for the Govt to invest in UK technology / science with co's such as ABDX.

Good luck, Brighty

It is worth pointing out that RNS' from N4P appear at various times of the day historically, not just at 7am, so anything can happen intra day here. e.g. the Covid invitro update came at 1.47pm. There have also been pivotal RNS' from N4P at 1.58pm, 2.22pm, 3.47pm, 9.15am and 8.10am in the last couple of years (not price monitoring or holding releases but 'news'. i.e. news is not issued just at 7am by N4P. This would indicate that an intra day RNS (about collaborations, Evotec, vaccine progress, MTA etc) is a real possibility based on previous timings of N4P's announcements. I'm going to be watching out for a number of N4P news announcements soon. Good luck, Brighty

When a company states "Significant progress continues towards a treatment for COVID-19" and the CEO is on record as saying "We believe this trial presents an opportunity for a significant UK scientific breakthrough" you have to feel very very good about your investment. There is very likely to be M&A activity with a major global pharmaceutical once the data is finally revealed. i.e. a massive licencing or a takeover deal. Check out the outlook part of the RNS from May of this year, below, which in particular articulates best why £10+ a share is a real possibility.

"Trial readouts are due over the coming months which we anticipate will add to the growing body of evidence supporting the use of inhaled interferon beta as a potential treatment for patients with COVID-19. These include data from our international SG018 Phase III trial and the US ACTIV-2 Phase II trial in COVID-19 outpatients. Beyond these trials Synairgen is in regular dialogue with government bodies and companies regarding the progress of inhaled interferon beta and its application as an effective treatment in both hospitalized and home-based patients.

"Synairgen will continue its commercialisation and manufacturing plans in order to scale up manufacturing and supply capacity, with the aim of making the drug readily available internationally and to meet potential commercial demand in the event of a regulatory approval".

Good luck, Brighty

Totally agree. If you want to get through to Boris and actually be heard you contact him via Joel Winton jwinton@no10.gov.uk and Munira Mirza mmirza@no10.gov.uk and Emily Wallis EWallis@no10.gov.uk Good luck, Brighty

Yes, at least ABDX will have the funds required which is clearly a huge positive as it takes the un-certainty away. Markets hate un-certainty so this is actually good news and is a huge positive but the Govt / civil servants have created this disgraceful scenario. We now know officially that the Johnson Govt is just a slogan machine "Build back better" "Northern Powerhouse", etc are just hollow words as they ignore UK scientific brilliance and plough billions in to Chinese tests and leave UK companies such as ABDX and ODX in the lurch. The civil servants and Govt should be ashamed. This is not backing Britain at all and the Gov'ts approach to UK business is exasperating and hugely damaging. Good luck, Brighty

Yes, ABDX will be back to January's 120p+ a share very soon on the back of positive news. It's just a case of waiting for good contract news to drop and the DHSC payment to be confirmed. It could happen very quickly. Good luck, Brighty

It is worth pointing out that Amgen paid $13 billion in cash for Otezla. So, £10+ a share for SNG is not as far fetched as some are suggesting. If you research the licencing and takeover transactions that have occurred in the pharmaceutical sector recently you will see that many are billion pound deals. This would put SNG in the £10+ a share bracket easily. I'm with The Lancet and Numis about the huge potential of SNG. I've been here since the 29p days and fully expect £10+ a share in due course. Good luck, Brighty

Below are the Top 10 global pharma companies. To those people who question billion dollar takeover and licencing deals think again. Look at the magnitutde of these companies:
• Johnson & Johnson – $56.1bn.
• Pfizer – $51.75bn.
• Roche – $49.23bn.
• Novartis – $47.45bn.
• Merck & Co. – $46.84bn.
• GlaxoSmithKline – $44.27bn.
• Sanofi – $40.46bn.
• AbbVie – $33.26bn.

SNG operates in a multi billion dollar sector. The above pharma companies (& many others) will be craving to get their hands on SNG. These co’s have a track record of paying big bucks for licencing and M&A activity. Not long to wait now for our next piece of stratospheric news which should see the SNG share price soar. Good luck, Brighty

"The board of Webis provides the following trading update for the year-ended 31 May 2021 which anticipates a US$ 1.1 million uplift in profitability over the previous year". Fantastic. Good luck, Brighty

Elcap isn't wrong. Those multi million trades appeared but they are no where to be seen now. They were very big. I'll be watching the trades closely tomorrow. Something is happening....Good luck, Brighty

Yes, the UK Govt / civil servants should be ashamed. "Build back better", "Backing UK diagnostic sector" etc all slogans for spin. Not the way to run a Govt. Abdx, ODX, NCYT all being hit by this disgraceful approach to procurement / tendering whilst awarding billions for Chinese tests. Quite shocking isn't it. In addition to MP's the people to write to / ring are Chris Wormald, Permanent Secretary, DHSC. Plus Dr Jenny Harries UK Health Security Agency Chief Executive. The main switchboard number for the UK Health Security Agency is 020 7654 8000. There's also Mark Hewlett Chief Operating Officer for Testing & Professor Steven Riley Director General Data & Analytics to write to / ring about ODX, ABDX, NCYT etc. You can find out their contact details by logging on to https://www.gov.uk/government/organisations/uk-health-security-agency. Good luck, Brighty

We might also be hearing that Patrick Chinnery and his team at the UK-CTAP advisory panel have signed off SDC1801 for Agile in the coming weeks. Both Agile and SRA737 are possibilities which the bod can rightly claim they have no prior knowledge on so they would not fall foul of regulatory rules on either. SRA737 can come at any time as can Agile. These 2 would see us past Thoth’s 28p a share I would suggest. Good luck all Sareum investors, Brighty

Amazing what a bit of positive news does . I'm hoping for more news prior to the AGM but for newbies and for those with a nervous disposition of late here's a reminder of the short to medium potential here:
1. Covid / Agile news update could / should be on the way very soon = licencing / takeover or more HNWI investing
2. SDC 1801 has a profile superior to dexamethasone = wow in the pharma sector = licencing / takeover possibility
3. SDC 1801 licencing deal on the back of point 2 has to be a fair assumption = BIG £££ deal in the sector
4. 737 Sierra licencing news (such as Gilead / Merck / AZ / Lilly etc taking it on from SRRA or SRRA still progressing with it) = commercial milestones commence = £££
5. II / TR1 / HNWI investment news via Peel Hunt and previous roadshows = more cash to progress to licencing
6. Global patents secured = ducks in a row = licencing / takeover or more HNWI investing
7. NCYT, SNG, AVCT, ODX, PYC etc demonstrate that pharma stocks with news can soar, as per my previous examples
8. OR as Thoth, WIP, Basil, Searle and many others have suggested here for many years a possible takeover
Good luck, Brighty

1. Covid / Agile news update could / should be on the way very soon = licencing / takeover or more HNWI investing
2. SDC 1801 has a profile superior to dexamethasone = wow in the pharma sector = licencing / takeover possibility
3. SDC 1801 licencing deal on the back of point 2 has to be a fair assumption = BIG £££ deal in the sector
4. 737 Sierra licencing news (such as Gilead / Merck / AZ / Lilly etc taking it on from SRRA or SRRA still progressing with it) = commercial milestones commence = £££
5. II / TR1 / HNWI investment news via Peel Hunt and previous roadshows = more cash to progress to licencing
6. Global patents secured = ducks in a row = licencing / takeover or more HNWI investing
7. NCYT, SNG, AVCT, ODX, PYC etc demonstrate that pharma stocks with news can soar, as per my previous examples
8. OR as Thoth, WIP, Searle and many others have suggested here for many years a possible takeover

I'm all for challenging the Parker / Mitchell approach to comms and PR, especially when you factor in point 7. It is dire and the launch pad was here in the summer for a much higher share price with some effective PR stories in the trade press and Sunday Times etc about Sareum. The lack of PR after the "SDC 1801 has a profile superior to dexamethasone" news was very frustrating indeed. I would go as far as to say it was incredible. It was clearly a cracking opportunity for the company to talk up its science. They failed to do so but lets get real they always have been dire with their PR in the 10+ years that I have held shares in Sareum. An NDA might have been the reason? That was / is my hope. However, look at 1-8 and you realise that we are all invested in something very special. OK the directors, perhaps, are poor communicators and a CEO with a more commercial approach to comms would be welcome. I would prefer to see Tim and John focus on the science and leave the deal making and PR to a more comms savvy ceo. In summary, we just need a better newsflow to keep the share price more stable than it currently is. The lack of news with AIM listed plc's is a tactic that has been proven time after time to impact negatively on a share price. So, come on Sareum we have 4 weeks until the AGM for news to drop. It did last year, twice. The share price never looked back after that. Here's to some news soon....Good luck all Sareum investors. Brighty